Virax raises $3.25 million

By Renate Krelle
Thursday, 13 January, 2005

Virax (ASX:VHL) has secured $3.25 million of the $4 million it was aiming to raise through a non-renounceable share purchase plan.

The funds will go towards the company's hepatitis B and prostate cancer programs. In late December 2004, Virax announced that a preclinical trial of a preliminary drug developed using its Co-X-Gene technology had induced an immune response against prostate cancer cells.

The company plans to commence animal toxicology work this year, with a view to moving into human trials.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd